Cynthia Smith's Insider Trades & SAST Disclosures
Cynthia Smith's most recent trade in T. Rowe Price Group Inc. was a trade of 19 Common Stock done at an average price of $119.7 . Disclosure was reported to the exchange on Dec. 27, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Cynthia Smith.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Group Inc. | Cynthia Smith F. | Director | Grant, award, or other acquisition of securities at price $ 119.68 per share. | 27 Dec 2024 | 19 | 4,331 (0%) | 0% | 119.7 | 2,274 | Common Stock |
| T. Rowe Price Group Inc. | Cynthia F. Smith | Director | Grant, award, or other acquisition of securities at price $ 112.40 per share. | 27 Sep 2024 | 20 | 4,311 (0%) | 0% | 112.4 | 2,248 | Common Stock |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2024 | 2,302 | 7,992 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2024 | 2,302 | 2,302 | - | - | Restricted stock units | |
| T. Rowe Price Group Inc. | Cynthia F. Smith | Director | Grant, award, or other acquisition of securities at price $ 117.11 per share. | 27 Jun 2024 | 19 | 4,291 (0%) | 0% | 117.1 | 2,225 | Common Stock |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 5,690 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units | |
| Protara Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 45,000 | 45,000 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 30,000 | 125,233 (0%) | 0% | 0 | Common Stock | |
| Spero Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 20,000 | 55,000 (0%) | 0% | 0 | Common Stock | |
| T. Rowe Price Group Inc. | Cynthia F. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 1,794 | 4,272 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2023 | 2,302 | 2,302 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2023 | 2,302 | 4,604 | - | - | Restricted stock units | |
| T. Rowe Price Group Inc. | Cynthia F. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2023 | 2,478 | 2,478 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 18,958 | 18,958 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 3,388 | 3,388 | - | - | Restricted stock units | |
| Protara Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 45,000 | 45,000 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 30,000 | 95,233 (0%) | 0% | 0 | Common Stock | |
| Spero Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 15,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 37,947 | 37,947 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 6,906 | 6,906 | - | - | Restricted stock units | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 20,100 | 20,100 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 13,700 | 65,233 (0%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Protara Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 20,100 | 20,100 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 13,700 | 51,533 (0%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Protara Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 3,750 | 21,750 | - | - | Stock Option (Right to Buy) | |
| Spero Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 2,629 | 2,629 | - | - | Stock Option (right to buy) | |
| Spero Therapeutics Inc | Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Akebia Therapeutics Inc. | Cynthia Smith | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 20,100 | 20,100 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Cynthia Smith | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 13,700 | 42,400 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | Cynthia Smith | None | Sale of securities on an exchange or to another person at price $ 12.10 per share. | 05 Jun 2020 | 4,567 | 37,833 (0%) | 0% | 12.1 | 55,261 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges